Comment – Active Surveillance vs. Adjuvant Therapy in Clinical Stage I Non-seminomatous Germ Cell Testicular Cancer

Obdržané:
4. 3. 2016

Autoři: D. Ondrus
Působiště autorů: st Department of Oncology, Comenius University Faculty of Medicine, St. Elisabeth Cancer Institute, Bratislava, Slovak Republic ¹
Vyšlo v časopise: Klin Onkol 2016; 29(2): 111-112
Kategorie: Komentář

Souhrn

Obdržané:
4. 3. 2016

Zdroje

1. Albers P, Albrecht W, Algaba F et al. Guidelines on testicular cancer: 2015 update. Eur Urol 2015; 68(6): 1054– 1068. doi: 10.1016/j.eururo.2015.07.044.

2. Coleman S, Stephenson A. Controversies in the management of stage I non-seminomatous germ cell tumors. Curr Urol Rep 2013; 14(5): 506– 510. doi: 10.1007/s11934-013-0362-5.

3. Peckham MJ, Barrett A, Husband JE et al. Orchidectomy alone in testicular stage I nonseminomatous germ cell tumors. Lancet 1982; 2(8300): 678– 680.

4. Donohue JP, Thornhill JA, Foster RS et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modification of technique and impact on ejaculation. J Urol 1993; 149(2): 237– 243.

5. Hahn NM, Sweeney CJ. Germ cell tumors: an update of recent data and review of active protocols in stage I and metastatic disease. Urol Oncol 2005; 23(4): 293– 302.

6. Sogani P, Whitmore WF, Herr HW et al. Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis. J Clin Oncol 1984; 2(4): 267– 270.

7. Sturgeon JF, Jewett MA, Alison RE et al. Surveillance after orchiectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 1992; 10(4): 564– 568.

8. Thompson PI, Nixon J, Harvey VJ. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol 1988; 6(10): 1597– 1603.

9. Ondrus D, Hornak M. Orchiectomy alone for clinical stage nonseminomatous germ cell tumors of the testis (NSGCTT): a minimum follow-up period of 5 years. Tumori 1994; 80(10): 362– 364.

10. Klepp O, Olsson AM, Henrikson H et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular cancer Group. J Clin Oncol 1990; 8(3): 509– 518.

11. Wishnow KI, Johnson DE, Swanson DA et al. Identifying patients with low risk clinical stage nonseminomatous testicular tumors who should be treated by surveillance. Urology 1989; 34(6): 339– 343.

12. Peckham MJ, Barrett A, Horwich A et al. Orchiectomy alone for stage I testicular nonseminoma. Br J Urol 1983; 55(6): 754– 759.

13. Albers P, Siener, R, Kliesch S et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group trial. J Clin Oncol 2003; 21(8): 1505– 1512.

14. Moul JW, Heidenreich A. Prognostic factor in low-stage nonseminomatous testicular cancer. Oncology 1996; 10(9): 1359– 1374.

15. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53(3): 478– 496. doi: 10.1016/j.eururo.2007.12.024.

16. Kollmannsberger C, Tandstad T, Bedard PL et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 2015; 33(1): 51– 57. doi: 10.1200/JCO.2014.56.2116.

17. Sturgeon JF, Moore MJ, Kakiashvili DM et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital‘s experience. Eur Urol 2011; 59(4): 556– 562. doi: 10.1016/j.eururo.2010.12.010.

18. Ondrus D, Ondrusova M, Hornak M et al. Nonseminomatous germ cell testicular tumors – clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only. Neoplasma 2007; 54(5): 437– 442.

19. Nichols CR, Roth B, Albers P et al. Active surveillance is the prefered approach to clinical stage I testicular cancer. J Clin Oncol 2013; 31(28): 3490– 3493. doi: 10.1200/JCO.2012.47.6010.

20. Tandstad T, Dahl O, Cohn-Cedermark G et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: The SWENOTECA management program. J Clin Oncol 2009; 27(13): 2122– 2128. doi: 10.1200/JCO.2008.18.8953.

21. Ondrus D, Kajo K, Stastna V et al. Controversies in the management of clinical stage I nonseminomatous germ cell testicular cancer. Klin Onkol 2015; 28(2): 112– 115. doi: 10.14735/amko2015112.

22. Albers P, Siener R, Krege S et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/ 94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26(18): 2966– 2972. doi: 10.1200/JCO.2007.12.0899.

23. Westermann DH, Studer UE. High-risk clinical stage Inonseminomatous germ cell tumors: the case for chemotherapy. World J Urol 2009; 27(4): 455– 461. doi: 10.1007/s00345-009-0456-3.

24. Pokrivcak T, Lakomý R, Vyzula R. News in adjuvant therapy of clinical stage I nonseminoma. Klin Onkol 2016; 29(2): 107– 110.